Citations

Showing 10 of 108094 citations.

Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome
Quigley, Eamonn M.M. , Markinson, Louise, Treasure, F. Peter, Lacy, Brian E. , Lacy, Brian E , Quigley, Eamonn M M , Stevenson, Alex

Mayo Clinic

Alimentary Pharmacology & Therapeutics | November 11, 2022 | Volume: 57 | Issue: 1 | Pages: 81-93

10.1111/apt.17310 | PMID 36369645 Get It

Summary Background MRx1234 is a live biotherapeutic product that contains a strain of Blautia hydrogenotrophica. It is in development for the treatment of irritable bowel syndrome (IBS). Aims To assess the efficacy and safety of MRx1234 in patients with IBS with predominant constipation (IBS‐C) or diarrhoea (IBS‐D) Methods We conducted a multicentre, randomised, double‐blind, placebo‐controlled, phase 2 trial. Patients aged 18–70 years in two parallel cohorts (IBS‐C; IBS‐D) were randomised (1:1) to MRx1234 or placebo for 8 weeks. The primary efficacy endpoint was overall responder rate—a composite of improved bowel habit (IBS‐C: stool frequency; IBS‐D: stool consistency) and abdominal pain intensity—for ≥50% of the treatment period in each cohort. Statistical testing was at a one‐sided 0.10 significance level. Results Of 366 randomised patients (164 IBS‐C; 202 IBS‐D), 365 received any study medication (177 MRx1234, 188 placebo). Numerically, although not statistically significantly different, more patients who received MRx1234 than placebo were overall responders in the IBS‐C (25.0% vs. 17.1%) and IBS‐D (23.4% vs. 17.8%) cohorts. Similar results were observed in the additional combined cohort analysis (24.1% vs. 17.5%; p = 0.063). For the components of the primary endpoint, significantly more patients on MRx1234 than placebo reported improvement in bowel habit in the IBS‐C, IBS‐D and combined cohorts, while improvements in abdominal pain were observed in each cohort. The safety profile of MRx1234 was similar to placebo. Conclusions MRx1234 has the potential to become a novel, safe treatment option for patients with IBS‐C or IBS‐D, and for those who have mixed symptoms or transition between subtypes. ClinicalTrials.gov #NCT03721107.
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702
Lee, Seohyuk , Ma, Chao , Shi, Qian , Kumar, Pankaj , Couture, Félix , Kuebler, Philip , Krishnamurthi, Smitha , Lewis, DeQuincy Andrew, Goldberg, Richard M. , Blanke, Charles D. , Shields, Anthony F. , Meyerhardt, Jeffrey A. , Kuebler, J. Philip , Goldberg, Richard M , Venook, Alan P , O'Reilly, Eileen M , Shields, Anthony F , Meyerhardt, Jeffrey A , Shi, Qian , Kumar, Pankaj , Tan, Benjamin, Venook, Alan P. , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | November 11, 2022 | Volume: 41 | Issue: 5 | Pages: 1079-1091

10.1200/jco.22.01637 | PMID 36367997 Get It

PURPOSE We sought to evaluate the independent and interactive associations of planned treatment duration, celecoxib use, physical activity, body mass index (BMI), diabetes mellitus, and vitamin B6 with oxaliplatin-induced peripheral neuropathy (OIPN) among patients with stage III colon cancer enrolled in a clinical trial. METHODS We conducted a prospective, observational study of 2,450 patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 trial, randomly assigned to 6 versus 12 cycles of adjuvant fluorouracil, leucovorin, and oxaliplatin chemotherapy with or without 3 years of celecoxib. OIPN was reported using the Common Terminology Criteria for Adverse Events (CTCAE) during and following completion of chemotherapy and the FACT/GOG-NTX-13 15-17 months after random assignment. Multivariate analyses were adjusted for baseline sociodemographic and clinical factors. RESULTS Patients assigned to 12 treatment cycles, relative to 6, were significantly more likely to experience higher-grade CTCAE- and FACT/GOG-NTX-13-reported neuropathy and longer times to resolution, while neither celecoxib nor vitamin B6 intake attenuated OIPN. Exercising ≥ 9 MET-hours per week after treatment relative to < 9 was associated with improvements in FACT/GOG-NTX-13-reported OIPN (adjusted difference in means, 1.47; 95% CI, 0.49 to 2.45; P = .003). Compared with patients with baseline BMIs < 25, those with BMIs ≥ 25 were at significantly greater risk of developing higher-grade CTCAE-reported OIPN during (adjusted odds ratio, 1.18; 95% CI, 1.00 to 1.40; P = .05) and following completion (adjusted odds ratio, 1.23; 95% CI, 1.01 to 1.50; P = .04) of oxaliplatin treatment. Patients with diabetes were significantly more likely to experience worse FACT/GOG-NTX-13-reported neuropathy relative to those without (adjusted difference in means, –2.0; 95% CI, –3.3 to –0.73; P = .002). There were no significant interactions between oxaliplatin treatment duration and any of these potentially modifiable exposures. CONCLUSION Lower physical activity, higher BMI, diabetes, and longer planned treatment duration, but not celecoxib use or vitamin B6 intake, may be associated with significantly increased OIPN severity.
Real-time sepsis prediction using fusion of on-chip analog classifier and electronic medical record
Sadasivuni, Sudarsan , Bhanushali, Sumukh Prashant , Banerjee, Imon , Sanyal, Arindam , Banerjee, Imon , Saha, Monjoy

Mayo Clinic

2022 IEEE International Symposium on Circuits and Systems (ISCAS) | November 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1635-1639

10.1109/iscas48785.2022.9937902 Get It

State-of-the-art management of dysplastic Barrett's esophagus
Vantanasiri, Kornpong , Iyer, Prasad G. , Vantanasiri, Kornpong

Mayo Clinic

Gastroenterology Report | November 11, 2022 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1093/gastro/goac068 | PMID 36381221 Get It

Abstract Endoscopic eradication therapy (EET) has become a standard of care for treatment of dysplastic Barrett’s esophagus (BE) and early Barrett’s neoplasia. EET mainly consists of removal of any visible lesions via endoscopic resection and eradication of all remaining Barrett’s mucosa using endoscopic ablation. Endoscopic mucosal resection and endoscopic submucosal dissection are the two available resection techniques. After complete resection of all visible lesions, it is crucial to perform endoscopic ablation to ensure complete eradication of the remaining Barrett’s segment. Endoscopic ablation can be done either with thermal techniques, including radiofrequency ablation and argon plasma coagulation, or cryotherapy techniques. The primary end point of EET is achieving complete remission of intestinal metaplasia (CRIM) to decrease the risk of dysplastic recurrence after successful EET. After CRIM is achieved, a standardized endoscopic surveillance protocol needs to be implemented for early detection of BE recurrence.
A Multisite Exploration of the Association between Critical Care Implementation Factors and Clinical Outcomes during the COVID-19 Pandemic
Silver, Santana , Redmond, Sarah , Jones, Kayla Christine , George, Emily , Zornes, Sarah, Leppin, Aaron L. , Harmon, Lori, Kumar, Vishakha K. , Kordik, Christina, Barwise, Amelia , Dong, Yue , Drainoni, Mari‐Lynn , Walkey, Allan J.

Mayo Clinic

No container title available | November 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2239482/v1 Get It

Abstract Background Little is known about the strategies used by critical care leaders to implement new practices in response to the COVID-19 pandemic. Prior studies have identified implementation factors, such as structured communication mechanisms and collaborative leadership styles, that facilitate implementation of new clinical practices. However, the association between differing implementation climates and COVID-19 clinical outcomes has not been examined. The purpose of this mixed methods study was to evaluate the relationship between implementation determinants and COVID-19 mortality rates. Methods We used mixed methods guided by the Consolidated Framework for Implementation Research (CFIR) to assess implementation factors that were associated with COVID-19 mortality rates across diverse critical care settings. Semi-structured qualitative interviews were conducted with critical care leaders and analyzed using the CFIR to rate the influence of constructs on implementation of new care practices. Qualitative and quantitative comparisons of CFIR construct ratings were performed between hospital groups with low versus high mortality rates. Results 31 clinical leaders were interviewed across 17 hospitals. Of the 13 relevant CFIR constructs, three constructs (implementation climate, leadership engagement, and engaging staff) had both qualitative and statistically significant quantitative correlations with mortality outcomes. An implementation climate governed by a trial-and-error approach was correlated with high COVID-19 mortality, while leadership engagement and engaging staff were correlated with low mortality. Another three constructs (needs of patient; organizational incentives and rewards; and engaging implementation leaders) were qualitatively different across mortality outcome groups, but these differences were not statistically significant. Seven constructs did not distinguish between low versus high mortality hospitals based on qualitative or quantitative comparison of CFIR construct ratings. Conclusions Application of the CFIR to identify and quantify constructs across critical care settings enabled us to characterize implementation barriers and facilitators at the practice, interpersonal, and provider level that were associated with COVID-19 mortality rates. Improving clinical outcomes during future public health emergencies will require reducing identified barriers associated with high mortality and harnessing salient facilitators associated with low mortality. Our findings suggest that clinical care implementation efforts should focus on avoiding trial-and-error approaches to adopting new practices, while promoting collaborative and engaged leadership styles.
Mutations of FH and IDH may induce gliomagenesis by similar mechanisms
Westbroek, Erick M. , Gupta, Sounak , Jenkins, Robert B. , Giannini, Caterina , Aldape, Kenneth , Raghunathan, Aditya , Jenkins, RB , Giannini, Caterina , Raghunathan, Aditya , Ida, Cristiane M.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | November 11, 2022 | Volume: 82 | Issue: 1 | Pages: 99-100

10.1093/jnen/nlac107 | PMID 36367829 Get It

Phosphaturic Mesenchymal Tumor
Barrera, Christian A. , Rhodes, Nicholas G. , Karp, John , Kearns, Ciléin

Mayo Clinic

RadioGraphics | November 11, 2022 | Volume: 43 | Issue: 1 | Pages: No page available

10.1148/rg.220185 | PMID 36367823 Get It

Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children
Berbert, Laura , Dallas, Johnathan, Newhams, Margaret M. , Chen, Sabrina , Ardoin, Stacy P. , Basiaga, Matthew L. , Crandall, Hillary , Dhakal, Sanjeev, Sagcal‐Gironella, Anna Carmela P. , Huie, Livie , Jones, Madelyn, Kim, Susan , Lionetti, Geraldina, Mannion, Melissa L. , Muscal, Eyal , Tejtel, S. Kristen Sexson , Villacis-Nunez, D. Sofia , Wu, Eveline Y. , Zambrano, Laura D. , Campbell, Angela P. , Patel, Manish M. , Randolph, Adrienne G. , Investigators, Overcoming COVID-19, Kong, Michele , Tarquinio, Keiko M. , Kücükak, Suden, FitzGerald, Madyson M., Worden, Julie, Levy, Emily R. , Martin, Lora , Malloch, Lacy , Clouser, Katharine N. , Walker, Tracie C. , Hall, Mark W., Staat, Mary Allen , Loftis, Laura L. , Smith, Lincoln , Feldstein, Leora R. , Jackson, Ashley , Levy, Emily R , Randolph, Adrienne G , Kong, Michele , Mannion, Melissa L , Staat, Mary A , Son, Mary Beth F. , Young, Cameron C. , Canny, Susan , Dhanrajani, Anita D. , Hobbs, Charlotte V. , James, Karen, Prahalad, Sampath , Schulert, Grant S , Investigators, Overcoming COVID-19, Cvijanovich, Natalie Z , Zinter, Matt S. , Schwartz, Stephanie P. , Hall, Mark W. , McGuire, John K. , Tenforde, Mark W.

Mayo Clinic

JAMA Network Open | November 11, 2022 | Volume: 5 | Issue: 11 | Pages: e2241622

10.1001/jamanetworkopen.2022.41622 | PMID 36367723 Get It

ImportanceMinimal data are available regarding the postdischarge treatment of multisystem inflammatory syndrome in children (MIS-C).ObjectivesTo evaluate clinical characteristics associated with duration of postdischarge glucocorticoid use and assess postdischarge clinical course, laboratory test result trajectories, and adverse events in a multicenter cohort with MIS-C.Design, Setting, and ParticipantsThis retrospective cohort study included patients with MIS-C hospitalized with severe illness and followed up for 3 months in an ambulatory setting. Patients younger than 21 years who were admitted between May 15, 2020, and May 31, 2021, at 13 US hospitals were included. Inclusion criteria were inpatient treatment comprising intravenous immunoglobulin, diagnosis of cardiovascular dysfunction (vasopressor requirement or left ventricular ejection fraction ≤55%), and availability of complete outpatient data for 3 months.ExposuresGlucocorticoid treatment.Main Outcomes and MeasuresMain outcomes were patient characteristics associated with postdischarge glucocorticoid treatment, laboratory test result trajectories, and adverse events. Multivariable regression was used to evaluate factors associated with postdischarge weight gain (≥2 kg in 3 months) and hyperglycemia during illness.ResultsAmong 186 patients, the median age was 10.4 years (IQR, 6.7-14.2 years); most were male (107 [57.5%]), Black non-Hispanic (60 [32.3%]), and Hispanic or Latino (59 [31.7%]). Most children were critically ill (intensive care unit admission, 163 [87.6%]; vasopressor receipt, 134 [72.0%]) and received inpatient glucocorticoid treatment (178 [95.7%]). Most were discharged with continued glucocorticoid treatment (173 [93.0%]); median discharge dose was 42 mg/d (IQR, 30-60 mg/d) or 1.1 mg/kg/d (IQR, 0.7-1.7 mg/kg/d). Inpatient severity of illness was not associated with duration of postdischarge glucocorticoid treatment. Outpatient treatment duration varied (median, 23 days; IQR, 15-32 days). Time to normalization of C-reactive protein and ferritin levels was similar for glucocorticoid duration of less than 3 weeks vs 3 or more weeks. Readmission occurred in 7 patients (3.8%); none was for cardiovascular dysfunction. Hyperglycemia developed in 14 patients (8.1%). Seventy-five patients (43%) gained 2 kg or more after discharge (median 4.1 kg; IQR, 3.0-6.0 kg). Inpatient high-dose intravenous and oral glucocorticoid therapy was associated with postdischarge weight gain (adjusted odds ratio, 6.91; 95% CI, 1.92-24.91).Conclusions and RelevanceIn this multicenter cohort of patients with MIS-C and cardiovascular dysfunction, postdischarge glucocorticoid treatment was often prolonged, but clinical outcomes were similar in patients prescribed shorter courses. Outpatient weight gain was common. Readmission was infrequent, with none for cardiovascular dysfunction. These findings suggest that strategies are needed to optimize postdischarge glucocorticoid courses for patients with MIS-C.
Cardiac epigenetic changes in VEGF signaling genes associate with myocardial microvascular rarefaction in experimental chronic kidney disease
Eirin, Alfonso , Chade, Alejandro , Chade, Alejandro R , Eirin, Alfonso

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | November 11, 2022 | Volume: 324 | Issue: 1 | Pages: H14-H25

10.1152/ajpheart.00522.2022 | PMID 36367693 Get It

Chronic kidney disease (CKD) often leads to left ventricular diastolic dysfunction (LVDD) and heart failure. Using a novel translational swine model of CKD-LVDD, we characterize the cardiac epigenetic landscape, identifying site-specific 5-methylcytosine changes in vascular endothelial growth factor (VEGF)-related genes associated with impaired angiogenesis and cardiac microvascular rarefaction. These observations shed light on the mechanisms of cardiac microvascular damage in CKD-LVDD and may assist in developing novel therapies for these patients.
Predicting Cholangiocarcinoma in Primary Sclerosing Cholangitis: Using Artificial Intelligence, Clinical and Laboratory Data
Hu, Chang , Juran, Brian D., McCauley, Bryan M. , Atkinson, Elizabeth J. , Eaton, John K. , Iyer, Ravishankar K. , Eaton, John, Ali, Ahmad , Lazaridis, Konstantinos N.

Mayo Clinic

No container title available | November 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2159551/v1 Get It

Abstract Background: Primary sclerosing cholangitis (PSC) patients have a risk of developing cholangiocarcinoma (CCA). Establishing predictive models for CCA in PSC is important. Methods: In a large cohort of 1,459 PSC patients seen at Mayo Clinic (1993-2020), we quantified the impact of clinical/laboratory variables on CCA development using univariate and multivariate Cox models and predicted CCA using statistical and artificial intelligence approaches. We explored plasma bile acid (BA) levels’ predictive power of CCA (subset of 300 patients, BA cohort). Results: Eight significant risk factors (false discovery rate: 20%) were identified with univariate analysis; prolonged inflammatory bowel disease (IBD) was the most important one. IBD duration, PSC duration, and total bilirubin remained significant (p<0.05) with multivariate analysis. Clinical/laboratory variables predicted CCA with cross-validated C-indexes of 0.68–0.71 at different time points of disease, significantly better compared to commonly used PSC risk scores. Lower chenodeoxycholic acid, higher conjugated fraction of lithocholic acid and hyodeoxycholic acid, and higher ratio of cholic acid to chenodeoxycholic acid were predictive of CCA. BAs predicted CCA with a cross-validated C-index of 0.66 (std: 0.11, BA cohort), similar to clinical/laboratory variables (C-index=0.64, std: 0.11, BA cohort). Combining BAs with clinical/laboratory variables leads to the best average C-index of 0.67 (std: 0.13, BA cohort). Conclusions: In a large PSC cohort, we identified clinical and laboratory risk factors for CCA development and demonstrated the first artificial intelligence based predictive models that performed significantly better than common risk scores. More predictive data modalities are needed for clinical adoption of these models.